Lv52
1200 积分 2024-03-06 加入
Recent advances in therapeutic targeting of the KRAS pathway in cancer
3天前
已完结
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
10天前
已完结
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
14天前
已完结
First-Line Therapy For Advanced Non–Clear Cell Renal Cell Carcinoma
1个月前
已完结
Recent advances in therapeutic targeting of the KRAS pathway in cancer
2个月前
已完结
USP1 inhibition: A journey from target discovery to clinical translation
2个月前
已完结
The new normal: immunomodulatory agents against sepsis immune suppression
3个月前
已完结
Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer
3个月前
已完结
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
3个月前
已完结
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
3个月前
已完结
皖公网安备34019202002308
